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INTERLEUKIN-6, also named B-cell stimulatory factor, is a
glycoprotein with a molecular weight of 26 kDa. Increased
serum levels of interleukin-6 (IL-6) are found in several
disease conditions. We investigated the importance of a
deteriorated kidney function upon IL-6 serum concentra-
tions. No relation was found between serum levels of IL-6
and s-creatinine, r 0.004. On the other hand, the serum
concentration of complement protein factor D and soluble
IL-2 receptor showed a good correlation to s-creatinine,
r 0.92 and 0.79, respectively. In conclusion, serum levels
ofIL-6 are not dependent upon a reduced kidney function.
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Introduction
Interleukins or cytokines are message molecules
which regulate important immunological functions.
All interleukins have low molecular weights.
Increased levels of interleukin-6 (IL-6), also known
as the B-cell stimulatory factor, or originally named
interferon f12 (IFNfl2) are found after a variety of
tissue responses ranging from minor stress, elective
surgery,
2 severe sepsis,
3 and in bacterial peritonitis
in patients undergoing continuous ambulatory
peritoneal dialysis, CAPD.
4 IL-6 seems to be
produced in most nuclear containing cells. It
appears to be one of the major mediators of the
reaction to viral and bacterial infections, inflamma-
tion and shock. It has also been experienced that
the level of IL-6 increases earlier than acute proteins
such as C-reactive protein and zl-antitrypsin.
IL-6 is a protein with 184 amino acids and a
molecular weight of about 26 kDa, so it can be
classified as a low molecular weight protein.
6
Therefore, it can be filtered through the glomeruli.
A reduced kidney function could be assumed to
increase serum IL-6 levels. Increased serum levels
of small molecular weight proteins i.e. fl-
microglobulin and factor D are seen in patients with
reduced glomerular filtration rate. 7’8 The aim of this
study was to investigate the influence of kidney
function upon serum levels of IL-6.
Normal sera: Sera from 25 normal blood donors
served as control for establishing the cut-off level
in the IL-6 assay.
Methods: Serum creatinine were measured by a
conventional technique at our department of
clinical chemistry. Factor D was measured by a
haemolysis technique.
9 The concentration is given
as a percentage ofnormal sera. Soluble interleukin-2
receptor (S-IL-2R) was measured using an ELISA
method (T-cell Science, Boston). Briefly, wells were
coated with a murine monoclonal antibody directed
against an epitope on the S-IL-2R molecule. A
horseradish peroxidase conjugated monoclonal
antibody directed against another epitope on S-IL-2
is used as the detecting (secondary) antibody.
IL-6 assay: Serum interleukin-6 (IL-6) was assayed
using an ELISA method (Innogenetics A.S.,
Antwerp, Belgium). Briefly, polystyrene micro-
plates were coated with sheep polyclonal anti-IL-6
antibodies. One hundred microlitres of the
respective samples were incubated for 2 h at 37C.
A murine monoclonal anti-IL-6 biotin-labelled
antibody was then added, followed by peroxidase
conjugated streptavidin. The substrate used was
tetramethylbenzidine and the developed colour was
read at 450 nm.
Materials and Methods
Patients: Twenty-one patients with adult polycystic
kidney disease were included in the study. Except
for their kidney disease they were all well and there
were no signs of an ongoing infection, or other
diseases. Serum creatinine values ranged from 80 to
1390/,mol/l.
Results
Normal sera: The mean absorbance, when subtract-
ing the background values, was 0.058. This value
corresponds to a concentration of 10 pg/ml, when
reading from the standard curve. The cut-off level
was set at 10 pg/ml, which corresponds to the
recommendation given by the manufacturer.
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FIG. 1. Shows the relation between serum concentration of IL-6 and
s-creatinine. The correlation coefficient was 0.0004.
Patients: Twelve of the patients had serum
concentrations of IL-6 below 10 pg/ml. One patient
had a very high serum concentration, 180 pg/ml. As
seen in Figure 1 no correlation was seen between
S-IL-6 and s-creatinine (r--0.004). There was no
correlation between serum levels of IL-6 and levels
of factor D and S-IL-2R. The correlation
coeflqcients were r 0.028 and r 0.018, respec-
tively. On the other hand, a very high correlation
was found between Factor D and s-creatinine as
seen in Figure 2a (r=0.92; p=0.0001). A
somewhat lower relation was observed between
S-IL-2R and s-creatinine (r=0.79; p=0.001)
(Figure 2b).
Discussion
1L-6 is a low molecular weight protein
synthesized in monocytes, though it can be
produced and secreted from all nuclear cells. It was
first identified by its ability to induce antibody
secretion by preactivated normal and Epstein--Barr
virus transformed human B-cells1 without first
inducing cellular proliferation. Apart from this
effect, it has been found that IL-6 induces
differentiation of cytotoxic T-cells from both
mature and immature T-cells.
lI
Several lines of evidence suggest that IL-6 is
involved in the pathogenesis of certain autoimmune
diseases.
12 High levels have been found in synovial
fluid in rheumatoid patients, but not in those with
active osteoarthritis. Furthermore, increased serum
levels of IL-6 have been found during allograft
rejection.
13 A close relation is also seen between
body temperature and IL-6 levels.
4 Since serum
levels of IL-6 are increased in several different
diseases, it could be of great importance to
investigate how a reduced kidney function
(a)
1400
1200
I000
800
600
400
200
0
0
y ,882x + 148,96, r2 =,852
0
0
0 Factor D R
200 400 600 800 I000 1200 1400 1600
s-Crealinine
(b) y 1,6Ix + 927.318. r2 ,628
3500.
3000
2500
0
o S-tL-2R
0
ooo
@
0 o
500
0 200 400 600 800 1000 1200 1400 1600
s-Creatinine
FIG. 2. (a) High correlation was round between serum levels of tactor D
and s-creatinine (r= 0.g2, p 0.0001). (b) Relation between serum
concentrations ot soluble IL-2R and s-creatinine (r 0.7g, p 0.001 ).
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influenced the measured concentrations. Under
normal circumstances interleukins, including IL-6,
are eliminated rapidly from plasma. There are many
possible ways for inactivation and elimination other
than the kidneys, for instance inactivation by
proteases,s binding to circulating soluble receptors
such as soluble TNF receptor,
6 to carriers such as
02-macroglobulin,
17 or to autoantibodies.
18 This
study shows clearly that a reduced kidney function
does not have a major effect on the serum levels of
IL-6. Therefore, measured levels are not falsely high
values recorded due to a deteriorated kidney
function, but reflect an inflammatory response
per se. These findings indicate that kidneys do not
contribute to any great extent to the clearance of
IL-6. The same condition seems to be valid for
interleukin-1. Radiolabelled IL-1 was injected to
nephrectomized rats, and there was only a small
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increase of serum IL-1 levels in these rats compared
to non-nephrectomized rats. The authors concluded
that less than 10% of IL-1 was cleared by the
kidney.
19 Though renal catabolism may play a role,
and tubular cells have been found to reabsorb
interleukins, (cf. Ref. 20) other elimination
pathways may account for an optimal clearance. In
patients with renal dysfunction it could be assumed
that some or several of the above mentioned
pathways are stimulated, leading to an enhancement
of inactivation of cytokines.
Factor D is a complement protein and the
S-IL-2R is a T-lymphocyte derived product with a
molecular weight of 45 kDa compared to 23.5 kDa
for Factor D. Serum levels for both these proteins
depend on kidney function and high correlation
coefficients to s-creatinine were found. Factor D
was seen to correlate even better for s-creatinine
than S-IL-2R. Recently it has also been shown that
circulating soluble tumour necrosis factor binding
protein is highly correlated to s-creatinine
21 in a
manner similar to S-IL-2R.
The high level of IL-6 in one of the patients was
puzzling. At the time of sampling there was no sign
of infection or inflammatory state. It is known that
IL-6 can be produced locally in the kidney due to
hypercellularity, for instance in renal cell carcino-
ma
22 or in mesangial proliferative glomerulone-
phritis.
23 It has also recently been shown that other
tumours may cause IL-6 production, for instance
myeloma and cardiac myxoma cells. It was not
completely ruled out that our patient might have
had a tumour, but at the time of sampling no
indication of neoplasm or other disorder was
observed. Follow-up has, however, not been
possible. It has been demonstrated that in vivo
administration of recombinant human tumour
necrosis factor to patients with metastatic cancer
leads to the induction of circulating levels of It-6.24
From an experimental point of view it has also been
shown that turnout necrosis factor influences IL-6
kinetics.
25
In conclusion, when evaluating serum levels of
IL-6 in different disease states there is no need for
correction due to a reduced glomerular filtration
rate.
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